Investor volatility plagues drug companies on new Chinese exchange.
作者信息
Mitchell Peter, Jing Fu
出版信息
Nat Biotechnol. 2010 Jan;28(1):9-10. doi: 10.1038/nbt0110-9.
PMID:20062025
Abstract
摘要
相似文献
1
Investor volatility plagues drug companies on new Chinese exchange.
Nat Biotechnol. 2010 Jan;28(1):9-10. doi: 10.1038/nbt0110-9.
2
Public companies get creative in raising finance.
Nat Biotechnol. 2010 Apr;28(4):301-2. doi: 10.1038/nbt0410-301.
3
Gold in the ivory tower: equity rewards of outlicensing.
Nat Biotechnol. 2006 May;24(5):509-15. doi: 10.1038/nbt0506-509.
4
How changes in drug-safety regulations affect the way drug and biotech companies invest in innovation.
Health Aff (Millwood). 2006 Sep-Oct;25(5):1309-17. doi: 10.1377/hlthaff.25.5.1309.
5
BioXell: an Italian biotech success story?
Nat Biotechnol. 2006 Sep;24(9):1045-6. doi: 10.1038/nbt0906-1045. Epub 2006 Sep 1.
6
Big pharma wants you.
Nat Biotechnol. 2006 Nov;24(11):1317-9. doi: 10.1038/bioent912.
7
The stampede to convertibles.
Nat Biotechnol. 2003 Aug;21(8):855. doi: 10.1038/nbt0803-855.
8
When your stock takes a nosedive.
Nat Biotechnol. 2006 Feb;24(2):144. doi: 10.1038/nbt0206-144.
9
The 802 million dollars fallacy.
Nat Biotechnol. 2004 Sep;22(9):1076. doi: 10.1038/nbt0904-1076a.
10
Capital faucet wide-open. Firms' healthcare-related investments up 16% in first half.
Mod Healthc. 1997 Sep 1;27(35):76.
Zotero 插件